534 related articles for article (PubMed ID: 30071993)
1. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
[TBL] [Abstract][Full Text] [Related]
2. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
[TBL] [Abstract][Full Text] [Related]
3. Sex-Related Differences in Ventricular Tachyarrhythmia Events in Patients With Implantable Cardioverter-Defibrillator and Prior Ventricular Tachyarrhythmias.
Krzowski B; Kutyifa V; Vloka M; Huang DT; Attari M; Aktas M; Shah AH; Musat D; Rosenthal L; McNitt S; Polonsky B; Schuger C; Natale A; Ziv O; Beck C; Daubert JP; Goldenberg I; Zareba W
JACC Clin Electrophysiol; 2024 Feb; 10(2):284-294. PubMed ID: 38032582
[TBL] [Abstract][Full Text] [Related]
4. QRS Morphology and the Risk of Ventricular Tachyarrhythmia in Cardiac Resynchronization Therapy Recipients.
Goldenberg I; Aktas MK; Zareba W; Tsu-Chau Huang D; Rosero SZ; Younis A; McNitt S; Stockburger M; Steinberg JS; Buttar RS; Merkely B; Kutyifa V
JACC Clin Electrophysiol; 2024 Jan; 10(1):16-26. PubMed ID: 38032575
[TBL] [Abstract][Full Text] [Related]
5. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
[TBL] [Abstract][Full Text] [Related]
6. Ventricular tachyarrhythmia recurrence in primary versus secondary implantable cardioverter-defibrillator patients and role of electrophysiology study.
Zaman S; Sivagangabalan G; Chik W; Stafford W; Hayes J; Denman R; Young G; Sanders P; Kovoor P
J Interv Card Electrophysiol; 2014 Dec; 41(3):195-202. PubMed ID: 25267274
[TBL] [Abstract][Full Text] [Related]
7. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
[TBL] [Abstract][Full Text] [Related]
8. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial.
Raitt MH; Connor WE; Morris C; Kron J; Halperin B; Chugh SS; McClelland J; Cook J; MacMurdy K; Swenson R; Connor SL; Gerhard G; Kraemer DF; Oseran D; Marchant C; Calhoun D; Shnider R; McAnulty J
JAMA; 2005 Jun; 293(23):2884-91. PubMed ID: 15956633
[TBL] [Abstract][Full Text] [Related]
9. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study.
Albert CM; Rosenthal L; Calkins H; Steinberg JS; Ruskin JN; Wang P; Muller JE; Mittleman MA;
J Am Coll Cardiol; 2007 Dec; 50(23):2233-40. PubMed ID: 18061071
[TBL] [Abstract][Full Text] [Related]
10. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction.
Coleman CI; Kluger J; Bhavnani S; Clyne C; Yarlagadda R; Guertin D; White CM
Heart Rhythm; 2008 Apr; 5(4):507-10. PubMed ID: 18362016
[TBL] [Abstract][Full Text] [Related]
11. Dyssynchrony and the risk of ventricular arrhythmias.
Kutyifa V; Pouleur AC; Knappe D; Al-Ahmad A; Gibinski M; Wang PJ; McNitt S; Merkely B; Goldenberg I; Solomon SD; Moss AJ; Zareba W
JACC Cardiovasc Imaging; 2013 Apr; 6(4):432-44. PubMed ID: 23579010
[TBL] [Abstract][Full Text] [Related]
12. Reduction in Ventricular Tachyarrhythmia Burden in Patients Enrolled in the RAID Trial.
Younis A; Goldenberg I; Farooq S; Yavin H; Daubert J; Raitt M; Mazur A; Huang DT; Mitchell BL; Rashtian MR; Winters S; Vloka M; Aktas M; Bernabei MA; Beck CA; McNitt S; Zareba W
JACC Clin Electrophysiol; 2022 Jun; 8(6):754-762. PubMed ID: 35738852
[TBL] [Abstract][Full Text] [Related]
13. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of noninvasive programmed stimulation in patients with implantable cardioverter defibrillator.
Futyma P; Sander J; Głuszczyk R; Maciołek M; Futyma M; Kułakowski P
Pacing Clin Electrophysiol; 2018 Dec; 41(12):1643-1651. PubMed ID: 30302762
[TBL] [Abstract][Full Text] [Related]
15. Left ventricle remodeling predicts the recurrence of ventricular tachyarrhythmias in implantable cardioverter defibrillator recipients for secondary prevention.
Lee WC; Chen HC; Chen YL; Tsai TH; Pan KL; Lin YS; Chen MC
BMC Cardiovasc Disord; 2016 Nov; 16(1):231. PubMed ID: 27871248
[TBL] [Abstract][Full Text] [Related]
16. T-peak to T-end interval for prediction of ventricular tachyarrhythmia and mortality in a primary prevention population with systolic cardiomyopathy.
Rosenthal TM; Stahls PF; Abi Samra FM; Bernard ML; Khatib S; Polin GM; Xue JQ; Morin DP
Heart Rhythm; 2015 Aug; 12(8):1789-97. PubMed ID: 25998895
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
[TBL] [Abstract][Full Text] [Related]
18. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
[TBL] [Abstract][Full Text] [Related]
19. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
Ellenbogen KA; Koneru JN; Sharma PS; Deshpande S; Wan C; Szymkiewicz SJ
JACC Clin Electrophysiol; 2017 Mar; 3(3):243-250. PubMed ID: 29759518
[TBL] [Abstract][Full Text] [Related]
20. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial.
Wilkoff BL; Ousdigian KT; Sterns LD; Wang ZJ; Wilson RD; Morgan JM;
J Am Coll Cardiol; 2006 Jul; 48(2):330-9. PubMed ID: 16843184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
